{{Drugbox
| Verifiedfields = changed
| Watchedfields = 
| verifiedrevid = 462091315
| IUPAC_name = 1-(2-<nowiki/>{4-[(3R,4R)-7-methoxy-2,2-dimethyl-3-phenyl-3,4-dihydro-2H-chromen-4-yl]phenoxy}ethyl)pyrrolidine
| image = Levormeloxifene.svg
| width = 

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = 

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 31477-60-8
| CAS_supplemental = 
| class = 
| ATC_prefix = 
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 35805
| IUPHAR_ligand = 
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 32935
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 9512UKZ352
| KEGG = 
| ChEBI = 
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 301327

<!--Chemical data-->
| C=30 | H=35 | N=1 | O=3
| molecular_weight = 457.604 g/mol
| SMILES = O(c1ccc(cc1)[C@@H]3c4c(OC([C@H]3c2ccccc2)(C)C)cc(OC)cc4)CCN5CCCC5
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C30H35NO3/c1-30(2)29(23-9-5-4-6-10-23)28(26-16-15-25(32-3)21-27(26)34-30)22-11-13-24(14-12-22)33-20-19-31-17-7-8-18-31/h4-6,9-16,21,28-29H,7-8,17-20H2,1-3H3/t28-,29+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = XZEUAXYWNKYKPL-WDYNHAJCSA-N
| synonyms = 
}}

'''Levormeloxifene''' ([[International Nonproprietary Name|INN]]) is an experimental [[selective estrogen receptor modulator]] (SERM) that was being developed as an alternative to [[Hormone replacement therapy (menopause)|estrogen replacement therapy]] for the treatment and prevention of postmenopausal bone loss. The development was stopped because of a high incidence of gynaecologic adverse events during [[clinical trial]]s.<ref name="pmid16532904">{{cite journal | vauthors = Ravn P, Nielsen TF, Christiansen C | title = What can be learned from the levormeloxifene experience? | journal = Acta Obstet Gynecol Scand | volume = 85 | issue = 2 | pages = 135â€“42 | year = 2006 | pmid = 16532904 | doi = | url = }}</ref> Levormeloxifene is the [[dextrorotation and levorotation|levorotatory]] [[enantiomer]] of [[ormeloxifene]].

==References==
{{Reflist|2}}


{{Estrogen receptor modulators}}

[[Category:Abandoned drugs]]
[[Category:Pyrrolidines]]
[[Category:Selective estrogen receptor modulators]]


{{genito-urinary-drug-stub}}